Table 2 Surface modification of dental implants with other growth factors
From: Dental implant bioactive surface modifications and their effects on osseointegration: a review
Author | Animal – bone site | Mode of surface modification | Length of study | Findings |
|---|---|---|---|---|
Anitua [32] | Goat – tibia and radius | 1. Ti (control) 2. Ti + PRGF | 8 weeks | % of BIC - Ti + PRGF: 51% - Ti: 22% |
Lan et al. [33] | Rabbit - femur | 1. Group 1: rhBMP-2 (1.0 mg) + rhbFGF (200 μg) 2. Group 2: rhBMP-2 (1.0 mg) + rhIGF-1 (250 μg) 3. Group 3: rhBMP-2 (1.0 mg) 4. Group 4: no growth factor (control) | 4 and 8 weeks | % of new bone formation - Group 1: 7.0% at 4 weeks, 10.0% at 8 weeks - Group 2: 7.6% at 4 weeks, 9.9% at 8 weeks - Group 3: 6.2% at 4 weeks, 8.0% at 8 weeks - Group 4: 5.0% at 4 weeks, 6.0% at 8 weeks |
Park et al. [34] | Rabbit - tibia | 1. Group 1: anodized under constant 300 voltage 2. Group 2: anodized under constant 300 voltage + FGF-FN fusion protein (65 μg/mL) | 12 weeks | Mean removal torque value - Group 1: 37.6 Ncm - Group 2: 44.8 Ncm % of BIC - Group 1: 76.4% - Group 2: 88.0% |
Nikolidakis et al. [35] | Goat – femoral condyle | 1. Control: Ti 2. Ti-TGF(0.5): Ti + 0.5 μg TGF-β1 3. Ti-TGF(1.0): Ti + 1.0 μg TGF-β1 | 6 weeks | % of BIC - Ti: 65% - Ti-TGF(0.5): 48% - Ti-TGF(1.0): 45% |
Schouten et al. [36] | Goat – Femoral condyle | 1. Screw type implant: St 2. St + CaP 3. St + CaP + TGF-β1 (1.0 μg) 4. Push-in type implant: Pi 5. Pi + CaP 6. Pi + CaP + TGF-β1 (1.0 μg) | 12 weeks | % of BIC - St: 44% - St + CaP: 58% - St + CaP + TGF-β1: 64% - Pi : 23% - Pi + CaP: 46% - Pi + CaP + TGF-β1: 52% |
Lee et al. [37] | Rabbit – tibia | 1. Group 1: anodized (under 300 voltage) 2. Group 2: anodized + 0.02 ml PLGA 3. Group 3: anodized + 0.02 ml PLGA/bFGF (10 ng bFGF) 4. Group 4: anodized + 0.2 ml PLGA/bFGF (100 ng bFGF) | 12 weeks | % of BIC - Groups 1: 31.4% - Group 2: 33.6% - Group 3: around 37% - Group 4: 44.7% |
Ramazanoglu et al. [38] | Pig – frontal skull | 1. AE (control) 2. CaP coated 3. CaP + rhBMP-2 inc 4. CaP + rhVEGFI65 inc 5. CaP + rhBMP-2 inc + rhVEGFI65 inc | 1, 2, and 4 weeks | % of BIC for ROI 1 + 4 - AE: 3.4% at 1 week; 11.5% at 2 weeks; 16.1% at 4 weeks - CaP: 5.2% at 1 week; 19.2% at 2 weeks; 23.5% at 4 weeks - CaP + BMP-2: 1.8% at 1 week; 15.5% at 2 weeks; 21.6% at 4 weeks - CaP + VEGF: 3.1% at 1 week; 15.2% at 2 weeks; 22.6% at 4 weeks - CaP + BMP-2 + VEGF: 3.3% at 1 week; 22.1% at 2 weeks; 23.2% at 4 weeks % of BIC for ROI 2 + 3 - AE: 10.6% at 1 week; 14.6% at 2 weeks; 20.1% at 4 weeks - CaP: 15.4% at 1 week; 22.6% at 2 weeks; 24.9% at 4 weeks - CaP + BMP-2: 8.2% at 1 week; 27.3% at 2 weeks; 23.6% at 4 weeks - CaP + VEGF: 8.5% at 1 week; 23% at 2 weeks; 24.4% at 4 weeks - CaP + BMP-2 + VEGF: 9.6% at 1 week; 31.7% at 2 weeks; 31.8% at 4 weeks |
Schliephake et al. [39] | Rat - tibia | 1. SAE (control) 2. SAE + OAS 3. SAE + OAS + rhVEGF-conjugated to complementary oligonucleotide strands | 1, 4, and 13 weeks | % of BIC for 1 and 4 weeks - SAE: 14.5% at 1 week; 40.6% at 4 weeks - SAE + OAS: 14.1% at 1 week; 40.2% at 4 weeks - SAE + OAS + VEGF: 15.1% at 1 week; 60.1% at 4 weeks % of BIC for 13 weeks All groups were between 75% to 80% with no significantly differences between groups |